Capital injection for new French drug company

Investee Company – Neuro 3D

Investee Company Country – France

Investee Company Business Type – Drug discovery company

Type of Financing – First round

Equity Providers – Sofinnova Partners and Apax Partners (Altamir & Cie)

Equity Leader (Individuals)- Denis Lucquin, Sofinnova Partners, and Dr. Laurent Ganem, Apax Partners

Debt Providers – N/A

Debt Type – N/A

Debt Leader (Individual) – N/A

Equity Amount – euro7.6 million

Total Deal Value – euro7.6 million

Other Advisors – Brault & Associes, SDM&C

Comments- Neuro 3D has been formed following an incubation phase of several months initiated and financed by Sofinnova. Denis Lucquin, general partner of Sofinnova Partners, commented: “The quality and the ambition of the team was the deciding factor in our decision to incubate this project”. The first round of financing, which totals FF50 million (euro7.6 million), was co-led by Sofinnova and Apax,with the latter investing through its LP fund and its quoted co-investment vehicle Altamir & Cie. The founders of Neuro 3D are Jean-Jacques Bourguignon, a chemist at l’Université Louis Pasteur, Strasbourg, specialising in neuroscience, and Dr. Jean-Paul Macher, President of the scientific advisory board of FORENAP. The President of the new company will be Charles Woler who also has many years of international experience in the biotechnology and pharmaceutical industries.